Patient baseline characteristics
| . | Total . |
|---|---|
| N = 21 (%) . | |
| Age at registration | |
| Median, y (range) | 58 (33-73) |
| Histology | |
| PTCL-NOS | 11 (52) |
| AITL | 4 (19) |
| ENKTL, nasal type | 3 (14) |
| ALK− ALCL | 2 (10) |
| MEITL | 1 (5) |
| Sex | |
| Female | 9 (43) |
| Male | 12 (57) |
| Race | |
| Asian | 2 (10) |
| Black or African American | 2 (10) |
| White | 11 (52) |
| Unknown | 6 (29) |
| Stage at diagnosis | |
| I | 2 (10) |
| II | 2 (10) |
| III | 3 (14) |
| IV | 9 (43) |
| Unknown | 5 (24) |
| IPI risk group | |
| 0-1 | 3 (14) |
| 2 | 6 (29) |
| 3 | 3 (14) |
| 4-5 | 1 (5) |
| Unknown | 8 (38) |
| No. of prior treatments | |
| 1 | 21 (100) |
| EBV status at diagnosis | |
| Negative | 7 (33) |
| Positive | 6 (29) |
| Not available | 8 (38) |
| Prior regimen | |
| CHOEP | 10 (48) |
| CHOEP + lenalidomide | 2 (10) |
| SMILE + RT | 2 (10) |
| Other (CHOP, CHOP + MTX, CHOP + pralatraxate, BV-CHP, SMILE and CHP) | 7 (33) |
| Conditioning regimen | |
| Carmustine/etoposide/cytarabine/melphalan (BEAM) | 19 (90) |
| Busulfan/cyclophosphamide/thiotepa | 1 (5) |
| Not reported | 1 (5) |
| Disease status before ASCT | |
| Complete metabolic response | 19 (90) |
| Partial metabolic response | 2 (10) |
| Disease status at study entry (after ASCT) | |
| Complete metabolic response | 20 (95) |
| Partial metabolic response | 1 (5) |
| . | Total . |
|---|---|
| N = 21 (%) . | |
| Age at registration | |
| Median, y (range) | 58 (33-73) |
| Histology | |
| PTCL-NOS | 11 (52) |
| AITL | 4 (19) |
| ENKTL, nasal type | 3 (14) |
| ALK− ALCL | 2 (10) |
| MEITL | 1 (5) |
| Sex | |
| Female | 9 (43) |
| Male | 12 (57) |
| Race | |
| Asian | 2 (10) |
| Black or African American | 2 (10) |
| White | 11 (52) |
| Unknown | 6 (29) |
| Stage at diagnosis | |
| I | 2 (10) |
| II | 2 (10) |
| III | 3 (14) |
| IV | 9 (43) |
| Unknown | 5 (24) |
| IPI risk group | |
| 0-1 | 3 (14) |
| 2 | 6 (29) |
| 3 | 3 (14) |
| 4-5 | 1 (5) |
| Unknown | 8 (38) |
| No. of prior treatments | |
| 1 | 21 (100) |
| EBV status at diagnosis | |
| Negative | 7 (33) |
| Positive | 6 (29) |
| Not available | 8 (38) |
| Prior regimen | |
| CHOEP | 10 (48) |
| CHOEP + lenalidomide | 2 (10) |
| SMILE + RT | 2 (10) |
| Other (CHOP, CHOP + MTX, CHOP + pralatraxate, BV-CHP, SMILE and CHP) | 7 (33) |
| Conditioning regimen | |
| Carmustine/etoposide/cytarabine/melphalan (BEAM) | 19 (90) |
| Busulfan/cyclophosphamide/thiotepa | 1 (5) |
| Not reported | 1 (5) |
| Disease status before ASCT | |
| Complete metabolic response | 19 (90) |
| Partial metabolic response | 2 (10) |
| Disease status at study entry (after ASCT) | |
| Complete metabolic response | 20 (95) |
| Partial metabolic response | 1 (5) |
BV-CHP, brentuximab, cyclophosphamide, doxorubicin and prednisone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; MTX, methotrexate; SMILE, dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide; RT, radiation therapy.